catharina.forsgren@ds.se. 2 Department of Medical Epidemiology & Biostatistics, Karolinska Institutet, Stockholm, Sweden The authors have no relevant affiliations or financial involvement with any ...
including a definition of clinical responders. In the phase 2 adaptive BELLINI trial, patients with early-stage triple-negative breast cancer received neoadjuvant nivolumab with or without ...